|
Targeted Prodrug Chemotherapy for Prostate Cancer
|
1R43CA139677-01A1
|
$159,988
|
$159,988
|
Wu, Jenny
|
ACADUCEUS PHARMACEUTICS, INC.
|
|
Dual Integrin and GRPR Targeted Radiotherapy of Prostate Cancer
|
1R43CA139678-01
|
$100,000
|
$100,000
|
WU, Jenny
|
ACADUCEUS PHARMACEUTICS, INC.
|
|
Development of an anti-PSA IgE to treat prostate cancer
|
1R41CA137881-01
|
$158,851
|
$158,851
|
SCHULTES, BIRGIT
|
ADVANCED IMMUNE THERAPEUTICS, INC.
|
|
Clinical and Immunologic Evaluation of ProstAtak for Prostate Cancer
|
4R44CA124032-02
|
$1,473,388
|
$1,473,388
|
Aguilar-Cordova, Estuardo
|
ADVANTAGENE, INC
|
|
PROSTATE, LUNG, COLO-RECTAL AND OVARIAN (PLCO) CANCER SCREENING TRIAL EXPANSION F
|
N01CN075022-063
|
$1,617,215
|
$404,304
|
FOUAD, MONA
|
ALABAMA UNIV BIRMINGHAM:1109410
|
|
Core Support for Cancer Center
|
5P30CA013330-37
|
$3,927,232
|
$78,545
|
GOLDMAN, Israel
|
ALBERT EINSTEIN COL OF MED YESHIVA UNIV
|
|
Skp2 in androgen-dependent proliferation of prostate cancer cells
|
1R01CA127901-01A2
|
$310,005
|
$310,005
|
ZHU, LIANG
|
ALBERT EINSTEIN COL OF MED YESHIVA UNIV
|
|
Bifunctional T cell receptor based immunotherapeutics
|
2R44CA097550-05A1
|
$1,000,000
|
$250,000
|
WONG, HING
|
ALTOR BIOSCIENCE CORPORATION
|
|
Characterizing Genetic Susceptibility to Breast and Prostate Cancer: The BPC3.
|
5U01CA098710-06
|
$550,218
|
$275,109
|
THUN, MICHAEL
|
AMERICAN CANCER SOCIETY, INC.
|
|
Radiation Therapy Oncology Group
|
2U10CA021661-33
|
$12,534,580
|
$7,019,365
|
CURRAN, WALTER
|
AMERICAN COLLEGE OF RADIOLOGY
|
|
Community Clinical Oncology Program Research Base
|
3U10CA037422-22S1
|
$26,578
|
$10,100
|
CURRAN, WALTER
|
AMERICAN COLLEGE OF RADIOLOGY
|
|
Community Clinical Oncology Program Research Base
|
5U10CA037422-22
|
$1,683,081
|
$639,571
|
CURRAN, WALTER
|
AMERICAN COLLEGE OF RADIOLOGY
|
|
RTOG Tissue Bank
|
5U24CA114734-05
|
$808,869
|
$80,887
|
CURRAN, WALTER
|
AMERICAN COLLEGE OF RADIOLOGY
|
|
American College of Radiology Imaging Network
|
5U01CA080098-11
|
$8,896,390
|
$1,112,049
|
Schnall, Mitchell
|
AMERICAN COLLEGE OF RADIOLOGY
|
|
QUALITY RESEARCH IN RADIATION ONCOLOGY: ACR PCS
|
5R01CA065435-11
|
$564,543
|
$112,909
|
WILSON, JESSE
|
AMERICAN COLLEGE OF RADIOLOGY
|
|
Primary Xenografts of Human Tissue as Surrogates of Cancer In Situ
|
1R43CA137737-01
|
$139,945
|
$69,973
|
Zwick, Michael
|
ANDROBIOSYS, INC.
|
|
Targeted Ceramic Nanovectors for Simultaneous Therapy and Imaging of Cancer
|
5R21CA133618-02
|
$129,423
|
$129,423
|
DEY, SANDWIP
|
ARIZONA STATE UNIVERSITY-TEMPE CAMPUS
|
|
Biomarker Detection Using NAPPA Tumor Antigen Arrays
|
7U01CA117374-05
|
$440,121
|
$110,030
|
LABAER, JOSHUA
|
ARIZONA STATE UNIVERSITY-TEMPE CAMPUS
|
|
Molecular Target Focused Discovery of Anticancer Drugs
|
5R01CA090441-07
|
$381,250
|
$53,375
|
PETTIT, GEORGE
|
ARIZONA STATE UNIVERSITY-TEMPE CAMPUS
|
|
Microfluidics-Based Platform for Screening Combinatorial Drug Treatments
|
5R21CA131891-02
|
$163,887
|
$163,887
|
Rege, Kaushal
|
ARIZONA STATE UNIVERSITY-TEMPE CAMPUS
|
|
PHASE I AND II CLINICAL TRIALS OF CANCER CHEMOPREVENTIVE AGENTS
|
N01CN035158-010
|
$1,432,000
|
$286,400
|
CHOW, SHERRY
|
ARIZONA UNIV:1109859
|
|
Bay Area Tumor Institute CCOP
|
5U10CA045461-20
|
$521,201
|
$67,756
|
Feusner, James
|
BAY AREA TUMOR INSTITUTE
|
|
Role of NCoR in Antiandrogen Resistance in Prostate Cancer
|
5R21CA129265-02
|
$172,688
|
$172,688
|
AGOULNIK, IRINA
|
BAYLOR COLLEGE OF MEDICINE
|
|
A Novel Inhibitor of Stat3 for Prostate Cancer Therapy
|
5R01CA104035-05
|
$280,899
|
$280,899
|
JING, NAIJIE
|
BAYLOR COLLEGE OF MEDICINE
|
|
Bioflavonoid Effects on EGF Signaling and Cell Cycle Pathways in Prostate Cancer
|
1R01CA128932-01A2
|
$318,513
|
$318,513
|
MARKAVERICH, BARRY
|
BAYLOR COLLEGE OF MEDICINE
|
|
Baylor College of Medicine Cancer Center
|
3P30CA125123-03S1
|
$117,279
|
$2,346
|
OSBORNE, C
|
BAYLOR COLLEGE OF MEDICINE
|
|
Baylor College of Medicine Cancer Center
|
3P30CA125123-03S2
|
$245,600
|
$4,912
|
OSBORNE, C
|
BAYLOR COLLEGE OF MEDICINE
|
|
Baylor College of Medicine Cancer Center
|
5P30CA125123-03
|
$1,515,000
|
$30,300
|
OSBORNE, C
|
BAYLOR COLLEGE OF MEDICINE
|
|
Mesenchymal Derived Growth Factors in Prostatic Cancer
|
2R01CA058093-16
|
$269,842
|
$269,842
|
ROWLEY, DAVID
|
BAYLOR COLLEGE OF MEDICINE
|
|
Co-evolution of the Reactive Microenvironment in Prostate Cancer Progression
|
5U54CA126568-04
|
$766,192
|
$766,192
|
ROWLEY, DAVID
|
BAYLOR COLLEGE OF MEDICINE
|
|
Role of FGFR1 signaling in distinct cell lineages in prostate cancer progresssion
|
1U01CA141497-01
|
$750,000
|
$750,000
|
SPENCER, DAVID
|
BAYLOR COLLEGE OF MEDICINE
|
|
Reversal of regulatory T cell function in prostate cancer
|
5R01CA121191-04
|
$258,529
|
$258,529
|
Wang, Rongfu
|
BAYLOR COLLEGE OF MEDICINE
|
|
Characterization of prostatic stem cells and prostate cancer-initiating cells
|
4R00CA125937-03
|
$249,000
|
$249,000
|
Xin, Li
|
BAYLOR COLLEGE OF MEDICINE
|
|
Virginia Mason Community Clinical Oncology Program
|
5U10CA035192-26
|
$430,954
|
$60,334
|
Vuky, Jacqueline
|
BENAROYA RESEARCH INST AT VIRGINIA MASON
|
|
Eastern Cooperative Oncology Group
|
5U10CA080775-11
|
$130,866
|
$2,617
|
ATKINS, MICHAEL
|
BETH ISRAEL DEACONESS MEDICAL CENTER
|
|
Targeting AR-NCoR Interaction in Prostate Cancer
|
5R01CA111803-03
|
$323,000
|
$323,000
|
BALK, STEVEN
|
BETH ISRAEL DEACONESS MEDICAL CENTER
|
|
The Role of PTEN and the PI3K Pathway in Prostate Cancer
|
5P01CA089021-08
|
$2,074,252
|
$2,074,252
|
CANTLEY, LEWIS
|
BETH ISRAEL DEACONESS MEDICAL CENTER
|
|
Androgen Receptor Regulation by Phosphorylation
|
5K99CA135592-02
|
$97,295
|
$97,295
|
Chen, Shaoyong
|
BETH ISRAEL DEACONESS MEDICAL CENTER
|
|
A Platform for Cancer Biomarker Validation: Image Fusion Using NIR Fluorescence
|
1R01CA134493-01A1
|
$745,852
|
$745,852
|
FRANGIONI, JOHN
|
BETH ISRAEL DEACONESS MEDICAL CENTER
|
|
A Rigid Multivalent Chemical Platform for Targeted Diagnostics and Therapeutics
|
5F32CA132332-02
|
$53,354
|
$53,354
|
Nasr, Khaled
|
BETH ISRAEL DEACONESS MEDICAL CENTER
|
|
Targeting Tumor Suppressor Phosphatases For Cancer Therapy
|
1U01CA141496-01
|
$825,000
|
$825,000
|
PANDOLFI, PIER
|
BETH ISRAEL DEACONESS MEDICAL CENTER
|
|
PTEN and ontogenesis and tumor suppression
|
5R01CA082328-12
|
$351,147
|
$87,787
|
PANDOLFI, PIER PAOLO
|
BETH ISRAEL DEACONESS MEDICAL CENTER
|
|
Characterization of Prostate Cancer with 3T MR
|
5R01CA116465-04
|
$371,857
|
$371,857
|
ROFSKY, NEIL
|
BETH ISRAEL DEACONESS MEDICAL CENTER
|
|
Harvard/Michigan Prostate Cancer Biomarker Clinical Ctr
|
5U01CA113913-05
|
$843,497
|
$843,497
|
SANDA, MARTIN
|
BETH ISRAEL DEACONESS MEDICAL CENTER
|
|
The function of RhoBTB proteins
|
5R01CA113559-04
|
$293,000
|
$73,250
|
Soltoff, Stephen
|
BETH ISRAEL DEACONESS MEDICAL CENTER
|
|
Geostatistical software for the analysis of individual-level epidemiologic data
|
2R44CA132347-02
|
$426,057
|
$140,599
|
GOOVAERTS, PIERRE
|
BIOMEDWARE
|
|
Assessing Localized Prostate Cancer Post-Treatment Outcomes Among Gay Men
|
1R03CA136114-01A1
|
$81,250
|
$81,250
|
Allensworth-Davies, Donald
|
BOSTON UNIVERSITY MEDICAL CAMPUS
|
|
The Role of Sirt1 in Prostate Cancer Cell Adhesion and Progression
|
1R21CA141036-01
|
$214,500
|
$214,500
|
Dai, Yan
|
BOSTON UNIVERSITY MEDICAL CAMPUS
|
|
Mechanisms of Action and Signaling by Steroid Hormone Antagonists
|
2R01CA101992-05A1
|
$260,271
|
$130,136
|
Faller, Douglas
|
BOSTON UNIVERSITY MEDICAL CAMPUS
|
|
The fuel sensing enzyme AMPK in the pathogenesis of prostate cancer
|
5R01CA118918-04
|
$224,058
|
$224,058
|
Luo, Zhijun
|
BOSTON UNIVERSITY MEDICAL CAMPUS
|
Total relevant funding to Prostate for this search: $293,932,674
|